ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PRTA / options
KMDA (49) MNPR (27) BLSM (42) FTH (29) ⌘ Pro Terminal →

Prothena Corporation plc (PRTA) Options Positioning, Max Pain & Unusual Sweeps

$8.47 -4.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.38

Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $455.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $8.47 (-4.62% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #937 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRTA compare to KMDA and MNPR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KMDA (Kamada Ltd.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $458.8M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, PRTA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRTA?
▼

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.38 (-1.02%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (5)Whales (9)SEC (3)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
$12 Bull$7 Base$6 Bear
📬 FREE PRTA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY PRTA SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (35% of score)

20D Institutional Volume Accumulation (±11.1% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (27% of score)

FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 54.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
18
Grade E$8.43+0.6% Next Q
Q2 (-2Q)
21
Grade E$8.48-0.9% Next Q
Q3 (-1Q)
23
Grade E$8.40+0.8% Next Q
Current
26
Grade E$8.47-10.5% Hist 90D α
Trajectory: E (18) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRTA currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.75) and Max Pain ($8.89) forces dealer call-delta covering toward $12.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±11.1%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PRTA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PRTA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)

  • ✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.50%▼ DESCENDING CHANNEL
2026-11-02O $9.10H $9.10L $8.47C $8.47VOL 370.1K
RES: $9.23SUP: $7.71SMA50: $8.75SMA200: $9.24
$12.08$10.90$9.72$8.54$7.36RES $9.23SUP $7.71$8.472026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRTA Butterfly Map → + Track PRTA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)

Health Care Rank #937 of 1016 ⚔️ KMDA vs PRTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRTA vs. KMDA, MNPR, BLSM, FTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #937 by composite RQD confidence (26/100, grade E) and #465 by equity capitalization ($455.9M). Within this direct 5-issuer industry benchmark cohort, PRTA leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. KMDA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PRTA at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRTA ACTIVE
Prothena Corporation plc
E 26/100 — — -35.0% -4.62% $455.9M Benchmark Subject
KMDA
Kamada Ltd.
D 49/100 — — — -3.14% $458.8M /kmda-vs-prta →
MNPR
Monopar Therapeutics Inc.
E 27/100 — — -17.4% -2.21% $482.7M /mnpr-vs-prta →
BLSM
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.60% $483.4M /blsm-vs-prta →
FTH
Faeth Therapeutics Inc.
E 29/100 — — -35.0% -0.32% $484.5M /fth-vs-prta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.7M -$244.1M -$163.6M -$163.6M $326.8M —
FY2024 (FY) 2024-12-31 $135.2M -$122.3M -$150.1M -$150.1M $547.1M —
FY2023 (FY) 2023-12-31 $91.4M -$147.0M -$133.9M -$133.9M — —

3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $8.47 (-4.62% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #937 in composite RQD confidence.

How does PRTA compare to KMDA and MNPR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KMDA (Kamada Ltd.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $458.8M) and MNPR (Monopar Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M). Among the 5-stock peer group, PRTA leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRTA?

Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRTA last traded at $8.47 (-4.62% on volume of 452,343 shares), positioning the stock -3.20% below its 50-day simple moving average ($8.75) and -8.33% below its 200-day simple moving average ($9.24). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 18.2% percentile with a 14-day RSI of 54.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($7.53 to $9.41).

PRTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PRTA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PRTA.

Direct Sub-Reports: PRTA RQD Cockpit PRTA 12M Forecast PRTA Earnings & Move PRTA Dividends & DRIP PRTA Insiders & 13F PRTA Whale Options PRTA Profit Sankey PRTA News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRTA — Prothena Corporation plc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRTA scores 26 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 5 out of 20, reflecting ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on capital or free cash flow, so any valuation case must rest on future cash generation rather than present earnings. The Whale 13F Flow pillar scores 9 out of 20, indicating institutional accumulation and options positioning that are weaker than the top of the scale. The Insider Conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest of the five pillars, which signals limited insider-side confidence in the source data. The Macro Regime Fit pillar scores 7 out of 20, with a beta of 1.0 and sector sensitivity that offers no defensive cushion. The Forensic Balance Sheet pillar scores 2 out of 20, with an Altman Z of 0.2, a Piotroski F of 2 out of 9, and Debt/Equity of 0.5, placing financial-distress risk at the center of the thesis. Taken together, the upside drivers are limited to a cash balance and a potential recovery in operating trajectory, while the tradeoffs are negative operating margins, distress-range forensic scores, and a rating that flags avoidance.

Business

Per the profile, Prothena Corporation plc is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, with a market capitalization of $0.5B. The source data does not describe specific products, customers, or revenue mechanics. Per the SEC financials, reported revenue was $9.7M in FY 2025, $135.2M in FY 2024, and $91.4M in FY 2023, indicating material year-to-year variation. Not available in source data for further detail on how the company monetizes its activities.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$9.7M$-214.6M$-244.1MN/A$-163.6M$307.5MN/A
FY 2024$135.2M$-154.6M$-122.3MN/A$-150.1M$471.4MN/A
FY 2023$91.4M$-191.0M$-147.0MN/A$-133.9MN/AN/A

Per the market data, operating margin and net margin are both -60%, and gross margin is 0%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 0.2, with a Piotroski F-Score of 2 out of 9 and Debt/Equity of 0.5. Cash declined from $471.4M in FY 2024 to $307.5M in FY 2025 while free cash flow remained negative in each reported period. Debt figures are not available in source data for any period.

Recent Catalysts & News Wire Analysis

  • Earnings event: Prothena plans to report third quarter 2026 financial results on November 5 (MARKET WIRE, marketscreener.com).
  • EPS expectation: A TradingView report references a Q3'26 EPS estimate of (0.23) USD (MARKET WIRE).
  • Partnership strategy: A Yahoo Finance headline questions whether the partnership strategy is a growth driver or a limitation, flagged as a CATALYST with a GREEN light.
  • Value-comparison coverage: A Yahoo Finance piece compares PRTA against CRMD for value investors (MARKET WIRE).
  • Allocation commentary: A Stock Traders Daily piece addresses price-sensitive allocations involving PRTA (MARKET WIRE).
  • Risk watch item: A Stock Titan page for Aspen Neuroscience (ASPE) is tagged to PRTA; its relevance to Prothena is not explained in source data.
  • Proprietary signals: Not available in source data; the Butterfly graph contains no proprietary signals.

Open Questions

  • What are PRTA's specific products, clinical or commercial pipeline, and revenue sources that explain the swing from $135.2M in FY 2024 to $9.7M in FY 2025?
  • What is the debt position, since debt is reported as N/A in every period while Debt/Equity is cited at 0.5?
  • What is the cash runway implied by $307.5M of cash against FY 2025 free cash flow of $-163.6M?
  • What is the basis and timing of the partnership strategy referenced in news coverage, and how would it affect revenue?
  • Which analyst estimates, price targets, and institutional or insider holders exist, given that those source sections are empty?

PRTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prothena Corporation plc (PRTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRTA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRTA Bull vs. Bear Conversation Board — What's Your Call at $8.47?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRTA 🐻 67% BEARISH CONVICTION
1. Pick Your Side on PRTA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.81 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRTA (E • RQD 26/100) a Buy at $8.88?

Welcome to the PRTA (Prothena Corporation plc) Roar Pit. Current RQD Composite is 26/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.19 (-19.0%)
Spot @ $8.88

Pump the brakes on PRTA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Prothena Corporation plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.28 (+27.0%)
Spot @ $8.88

PRTA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRTA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.88 (52-wk range $7.73 - $11.80), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%